Zhixun Finance APP News, Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its holding subsidiary, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. (referred to as Kangchuanji Pharmaceutical) has received the "Drug Registration Certificate" for Dopamine Hydrochloride Injection approved and issued by the National Medical Products Administration (Acceptance Number: CYHS2301483).

Dopamine Hydrochloride Injection is suitable for shock syndrome caused by myocardial infarction, trauma, endotoxin septicemia, heart surgery, renal insufficiency, congestive heart failure, etc.; especially for shock patients who cannot be corrected after supplementing blood volume, especially those with oliguria and normal or low peripheral vascular resistance.